A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19-64
SponsorAddpharma Inc.
About this trial
A Study to Evaluate the Safety and Pharmacokinetics of AD-231 Compared to Coadministration of AD-231A, AD-231D and AD-231C
Eligibility criteria
Qualifiers
Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
The Age equal to or greater than 19 and under 65 years in healthy volunteers at the time of screening visit
Disqualifiers
Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
Other exclusions applied
Trial design
Treatments tested in this trial
- AD-231
- AD-231A, AD-231D and AD-231C
Treatment groups
60 Participants
are divided into 2 treatment groupsLocations
1H Plus Yangji Hospita Seoul South Korea
Sponsors and collaborators
Addpharma Inc.
Lead sponsor
Source ClinicalTrials.gov